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ABSTRACT 
Decision analytic models in healthcare require baseline health related quality of life (HRQoL) 
data to accurately assess the benefits of interventions.  The use of inappropriate baselines such 
as assuming the value of perfect health (EQ-5D = 1) for not having a condition may 
overestimate the benefits of some treatment and thus distort policy decisions informed by cost 
per QALY thresholds. 
 
The primary objective was to determine if data from the general population are appropriate 
for baseline health state utility values (HSUVs) when condition specific data are not 
available. 
 
Methods: Data from four consecutive Health Surveys for England were pooled.  Self-reported 
health status and EQ-5D data were extracted and used to generate mean HSUVs for cohorts 
with or without prevalent health conditions.  These were compared with mean HSUVs from 
all respondents irrespective of health status. 
 
Results: Over 45% of respondents (n=41,174) reported at least one health condition and 
almost 20% reported at least two.  Our results suggest that data from the general population 
could be used to approximate baseline HSUVs in some analyses but not all.  In particular, 
HSUVs from the general population would not be an appropriate baseline for cohorts who 
have just one health condition.  In these instances, if condition specific data are not available, 
data from respondents who report they do not have a prevalent health condition may be more 
appropriate.  Exploratory analyses suggest the decrement on HRQoL may not be constant 
across ages for all conditions and these relationships may be condition specific.  Additional 
research is required to validate our findings. 
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INTRODUCTION 
Agencies such as the National Institute for Health and Clinical Excellence (NICE) produce 
national guidance on the provision of new health technologies and their recommendations are 
informed by reviews of clinical and economic evidence.  To facilitate consistent 
reimbursement recommendations across all disease areas interventions are appraised using a 
decision rule based on the incremental cost per quality adjusted life year (QALY).  The cost 
per QALY results are estimated using decision analytic models which describe the clinical 
pathway of health conditions or systems mathematically. 
 
Analytic models frequently compare the benefits of treatments that have the potential to 
alleviate a health condition or avoid a clinical event.  Conditions and events are described by 
health states in the models and the health related quality of life (HRQoL) or  health state 
utility values (HSUV) associated with these are generally obtained from clinical trials or 
observational studies.  The baseline HRQoL used to represent the HSUVs for individuals 
without these conditions or events is equally relevant as these data are used to assess the 
HRQoL gain in alleviating or avoiding the condition or event.  Ideally the baseline HSUVs 
would be derived from people without specific condition(s) using the definitions of health 
states in the model.  However, these data are rarely available and a baseline of full health is 
commonly assumed.[1]  As the average person still has other health problems, this 
assumption overestimates the benefits of treatment[2,3] and it has been suggested that on 
average, a treatment will increase HRQoL to the same level as persons without the 
condition.[4]  The baseline HSUVs used in decision models has important consequences as 
these data could distort a policy decision based on a cost per QALY threshold thus 
undermining efficient resource allocation.[5] 
 
When condition specific baseline data are not available, one solution has been to use age-
adjusted HSUVs obtained from the general population (irrespective of health condition).[1,2]  
These data will include individuals with the condition of interest hence an element of double 
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counting is inevitable.  However, unless the prevalence of the health condition is high or the 
affect on HRQoL is substantial, intuitively one would expect the HRQoL of the average 
person without a particular health condition to be similar to the HRQoL of the average person 
of a similar age in the general population.  Researchers have shown that in cardiovascular 
disease (CVD) the cost per QALY results are of a similar magnitude when estimated using 
either a baseline from the general population or a baseline from respondents with no history 
of CVD.[5] 
 
The primary objective of the current study is to determine if this finding generalises to other 
conditions and thus if data from the general population are appropriate as baseline HSUVs in 
decision models.  Specifically, we compare the HRQoL for subgroups who have a particular 
prevalent health condition (irrespective of other conditions) with a) the HRQoL from similar 
aged subgroups who do not have the condition (irrespective of other health conditions) and b) 
the HRQoL from similar aged subgroups irrespective of health status (i.e. the general 
population).  As a secondary analysis, we compare the HRQoL for subgroups who have just 
one particular prevalent health condition with a) the HRQoL from similar aged subgroups 
who do not have any condition and b) the HRQoL from similar aged subgroups irrespective 
of health status (i.e. the general population). 
 
 
METHODS 
Data: We used HRQoL data and information on health status collected in the Health Survey 
for England (HSE).[6]  The HSE is an annual survey conducted on randomly selected samples 
of the population living in private households in England.[HSE]  The current study pools data 
collected during the 2003, 2004, 2005 and 2006 surveys.  Information on health status was 
obtained from responses to the following question: “ Do you have any long-standing illness, 
disability or infirmity? By long-standing I mean anything that has troubled you over a period 
of time, or that is likely to affect you over a period of time?”  Details were obtained for a 
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maximum of six types of long-standing illnesses per person and responses were coded into 39 
different health conditions.  Two additional codes: “unclassifiable” and “complaint no longer 
present” were treated as no condition in our analyses. 
 
HRQoL information was collected using the widely used generic questionnaire, the EQ-
5D.[7]   The EQ-5D contains five attributes of health status including: mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression.  Each attribute is measured by a 
question with three possible responses: no problem, some problem, or severe problem.  The 
combination of all possible responses leads to 243 (3^5) distinct health states.  A random 
sample of the UK general public valued a sample of these health states using time trade-off 
techniques.[7]  The resulting algorithm, which was used to calculate HSUVs for the current 
study, produces a range of -0.59 to 1, whereby 1 represents perfect health, 0 represents death 
and negative values represent health states considered to be worse than death. 
 
Analysis:  
Generally patients in decision analytic models are defined to match the demographic 
characteristics of patients who would receive the intervention under evaluation in clinical 
practice.  Consequently, a typical patient will have concurrent health conditions and for older 
aged cohorts, a substantial proportion of patients will have additional prevalent health 
conditions.  However, the effectiveness and HRQoL evidence used to assess the benefits of 
treatments may be derived from studies using strict recruitment criteria and patients with 
comorbidities can be excluded from these.  As the baseline needs to reflect the definitions and 
data used in the model, we perform a series of analyses as described below. 
i) The primary analyses test whether data from the general population can be used as the 
baseline HRQoL when data from cohorts with a specific health condition (irrespective of 
other health conditions) are used to assess the benefits of treatment.  We compare mean EQ-
5D scores for these subgroups with mean EQ-5D scores from a) respondents of a similar age 
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who did not have the specific health condition and b) respondents of a similar age irrespective 
of health status (i.e. the general population). 
ii) The secondary analyses test whether data from the general population can be used as 
the baseline HRQoL when data from cohorts with a single health condition are used to assess 
the benefits of treatment.  We compare mean EQ-5D scores for these subgroups with mean 
EQ-5D scores from a) respondents of a similar age who do not have any health condition and 
b) respondents of a similar age irrespective of health status (i.e. the general population). 
iii) Exploratory analyses were also performed to test a) if the decrements on HRQoL for 
cohorts with a specific health condition (irrespective of other health conditions) are 
comparable to the decrements for cohorts with the single specific health condition (and no 
other condition) and b) if the decrements on HRQoL are constant across age. 
 
All analyses were performed in STATA (v 11).  Using the minimal important difference for 
the EQ-5D (0.074) as a benchmark,[8] and assuming a SD of 0.20 in EQ-5D scores, we used 
subgroups of greater than 64 (256) respondents for having the power to detect a mean 
difference of 0.10 (0.05) with 80% power and 5% two-sided significance.  The analyses were 
weighted using the individual level self-administered questionnaire weights.[6]  Statistical 
significance for the weighted mean EQ-5D scores was assessed using the 95% confidence 
intervals (CI) of the mean whereby if the CIs do not overlap there is a statistically significant 
difference between the groups.[9] 
 
 
RESULTS 
Of the 41,174 respondents who completed the EQ-5D questionnaire, 44.5% (18302/41174) 
were male, and the mean age was 48.6 (SD: 18.5) years for males and 48.5 (SD: 19.0) years 
for females.  54.5% (22449/41174) reported they did not have a history of a health condition, 
26.1% (10762/41174) reported just one condition and 19.3% (7963/41174) reported at least 
two conditions.  The most prevalent condition (Table A1 appendix) was 
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“arthritis/rheumatism/fibrositis” at 10.1% (4145/41174) of the sample followed by 
“hypertension/high blood pressure” at 7.7% (3172/41174).  Prevalence of comorbid health 
conditions varied by primary health condition and by age.  The proportion of respondents 
with more than one health condition ranged from 84.2% (123/146) of respondents with “other 
bladder problems/incontinence” to 54.0% (1325/2452) of respondents with “asthma”.  For 
respondents (n=4,212) aged 40 years or younger who reported at least one health condition, 
just 22.2% had at least one other condition while 57.4% of respondents (n=1,638) aged over 
80 years who reported at least one health condition had at least one other condition. 
 
The mean EQ-5D for all respondents (n=41,174) was 0.868 (range:-0.594 to 1).  Respondents 
(22,449) who reported no health condition had a mean EQ-5D of 0.949 (range: -0.371 to 1) 
while respondents who reported one, or more than one health condition had mean EQ-5D 
scores of 0.821 (range: -0.594 to 1) and 0.654 (range: -0.594 to 1) respectively. 
 
i) Primary analyses: With the exception of respondents who had a history of “hayfever” 
(n=416), all mean EQ-5D scores for respondents who reported they had a specific health 
condition irrespective of whether they had other health conditions too (Table 1) were lower 
than the mean EQ-5D scores for the subgroups who either did not have the condition or the 
subgroups irrespective of health status.  Four of the 39 subgroups had less than 64 
respondents hence were not assessed in terms of significant differences in mean scores.  As 
the confidence intervals of the mean EQ-5D scores did not overlap for 29/35 pairs when 
comparing with subgroups without the condition and 27/35 pairs when comparing with 
subgroups irrespective of health condition, the differences were significant at the p < 0.05 
level.  Comparing the mean EQ-5D scores for respondents not affected by a condition with 
the corresponding mean scores for respondents irrespective of health condition, the 
confidence intervals of the paired mean scores overlapped. 
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INSERT TABLE 1: Mean EQ-5D scores for respondents subgrouped by health condition 
 
 
These data can be used to assess the average absolute or relative effect on HRQoL compared 
to the average person of a similar age who does not have the named condition, or the average 
person of a similar age irrespective of health status.  The condition “complaints of the 
teeth/mouth or tongue” produced the largest average decrement on HRQoL compared to the 
subgroup who did not have the condition (absolute = 0.345, relative = 39%) and the subgroup 
from the general population (absolute = 0.344, relative = 39%).  The condition “a history of 
stroke” produced the second largest average decrement on HRQoL compared to the subgroup 
who did not have the condition (absolute = 0.287, relative = 35%) and the subgroup from the 
general population (absolute = 0.282, relative = 34%).  When compared to subgroups without 
the health condition, and when compared to subgroups irrespective of health status, 31/39 of 
the differences in mean EQ-5D scores were greater than the minimal important difference 
(|0.074|) for the EQ-5D.[8] 
 
ii) Secondary analyses: For the subgroups who reported they had a single specific health 
condition, compared to subgroups of a similar age who reported no health condition, with the 
exception of respondents who had a history of “hayfever” (n=186), and respondents who had 
a history of “poor hearing/deafness” (n=146) all mean EQ-5D scores were lower for the 
subgroups with the condition (Table 2).  10 of the 39 subgroups had less than 64 respondents 
hence were not assessed in terms of significant differences in mean scores.  Of the remaining 
29 pairs, compared to subgroups who reported no condition, as the confidence intervals of the 
mean EQ-5D scores did not overlap for 22 comparisons the differences were significant at the 
p < 0.05 level.  When comparing the mean EQ-5D scores for subgroups with a single health 
condition with subgroups of a similar age irrespective of health status (i.e. general 
population), of the 29 subgroups involving more than 64 respondents, the mean scores were 
greater for 13 of the subgroups with a single condition.  As the CIs for the mean EQ-5D 
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scores did not overlap for 8 of the 13 pairs, these differences were statistically significant (p < 
0.05).  For the remaining 16/29 subgroups with mean EQ-5D scores smaller than those of 
similar aged subgroups irrespective of health status, the CIs of the mean EQ-5D scores did 
not overlap for 5/16 comparisons (p < 0.05). 
 
 
INSERT TABLE 2: Mean EQ-5D scores for respondents with a single health condition 
 
 
These data can be used to assess the average absolute or relative effect on HRQoL for a single 
condition in isolation compared to the average person of a similar age who does not have any 
condition, or the average person of a similar age irrespective of health status.  The condition 
“complaints of the teeth/mouth or tongue” produced the largest average decrement on 
HRQoL compared to the subgroup who had no condition (absolute = 0.290, relative = 30%) 
and the subgroup from the general population (absolute = 0.245, relative = 27%).  The 
condition “a history of stroke” produced the second largest average decrement on HRQoL 
compared to the subgroup who had no condition (absolute = 0.254, relative = 27%) and the 
subgroup from the general population (absolute = 0.106, relative = 13%).  When compared to 
subgroups without a health condition, 20/39 of the differences in mean EQ-5D scores were 
greater than the minimal important difference (|0.074|) for the EQ-5D while just 12/39 of the 
differences were greater than the MID when comparing to the subgroups irrespective of 
health status.[8] 
 
iii) Exploratory analyses 
a) Comparing average decrements on HRQoL for cohorts with a specific health 
condition (irrespective of other health conditions) with average decrements for corresponding 
cohorts with just the single specific health condition.  In 14 of the 39 conditions, the average 
decrements on HRQoL were more than halved for the subgroups with just the one health 
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condition (versus subgroups with no condition) compared to the average decrements on 
HRQoL for the subgroups with the same condition irrespective of other conditions (versus 
subgroups without the specific condition irrespective of other conditions) .  For example the 
average relative decrement was 2% for respondents (n=1127) with just “asthma” when 
compared to respondents of a similar age without any health condition versus an average 
relative decrement of 10% for respondents (n=2452) with “asthma” and any other health 
condition when compared to respondents of a similar age without asthma.  These data suggest 
comorbidities impose an additional decrement on HRQoL and the implication of this should 
be considered on an individual basis when calculating decrements attributed to the alleviation 
of conditions or avoidance of clinical events in economic models. 
 
b) Comparing decrements on HRQoL across age groups 
Using the full dataset, HRQoL decreased by age (Figure 1) in general irrespective of the 
number of health conditions.  The rate of decrease in HRQoL by age was greatest in 
respondents aged over 65 years.  Comparing the mean EQ-5D scores for the youngest and 
oldest aged cohorts subgrouped by health status, the reduction in HRQoL was greatest for 
respondents with at least one health condition. 
 
INSERT FIGURE 1: Mean EQ-5D scores stratified by age and number of health conditions 
 
Potential trends in decrements in HRQoL by age for the individual health conditions were 
assessed visually by plotting mean EQ-5D scores for age and health condition stratified 
subgroups together with the average absolute and relative decrements (Figure 2, Figure 3 & 
Figure 4 supplied in the appendix).  Due to small numbers in the age stratified data, these 
exploratory analyses were performed for the most prevalent health conditions only and the 
data were compared to respondents who did not have the relevant condition.  For the cohort 
(n=2484) with “ back problems/slipped disc/spine/neck” plus any other health condition, the 
average relative decrement on HRQoL compared to respondents without the condition 
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increased by age up to the age of 80 years (Figure 2a).  This trend was also visible in the 
cohort (n=1106) with just “ back problems/slipped disc/spine/neck” (Figure 2b) when 
compared to respondents with no health condition.  The age stratified average absolute 
decrements (range 0.19 to 0.29) were similar for the cohorts with or without comorbid health 
conditions.  Compared to the respondents without the condition, as the CIs for the mean EQ-
5D scores did not cross, all the age stratified decrements were statistically significant at the 
95% level. 
 
INSERT FIGURE 2: Mean EQ-5D scores and decrements on HRQoL for respondents with 
“back problems/slipped disc/spine/neck” 
 
Conversely, for the cohort (n= 3172) with “hypertension/high blood pressure/blood” plus any 
other condition the relative decrement on HRQoL compared to respondents without the 
condition decreased by age with the largest effects observed in respondents younger than 60 
years (Figure 3a).  The average effect on HRQoL was much smaller across all age groups for 
the cohort with just “hypertension/high blood pressure/blood” (n=974) compared to the 
average effect on HRQoL for the cohort with “hypertension/high blood pressure/blood” and 
any other health condition (Figure 3b). 
 
For the cohort (n=4145)  with “arthritis/rheumatism/fibrositis” plus any other health 
condition, the average relative decrement on HRQoL compared to subgroups without the 
condition decreased slightly by age for respondents aged over 40 years (Figure 4).  
Conversely, for the cohort (n=1358) with just “arthritis/rheumatism/fibrositis” and no other 
condition, compared to respondents with no health condition, the average relative decrement 
on HRQoL increased by age.  When comparing the mean EQ-5D scores from cohorts with 
just “arthritis/rheumatism/fibrositis” with the mean EQ-5D scores for cohorts with 
“arthritis/rheumatism/fibrositis” plus any other condition the confidence intervals of the mean 
EQ-5D scores did not overlap for the cohorts aged between 40 years and 70 years only.  All 
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age and condition specific mean EQ-5D scores used in the analyses which are not discussed 
in the article are provided in the online appendix. 
 
 
 
DISCUSSION 
This study provides EQ-5D scores obtained from non institutionalised residents in England 
stratified by self-reported history of prevalent health condition(s) and age (where sample sizes 
permit).  Our results suggest that data from the general population irrespective of health status 
could be used in place of condition specific data to represent the HSUVs associated with not 
having a particular health condition in some analyses but not all.  In particular, our analyses 
show that HSUVs from the general population would not be appropriate for cohorts who have 
just one health condition.  In these instances, if the condition specific data are not available, 
age stratified mean HSUVs from respondents who report they have none of the prevalent 
health conditions could be used. 
 
Not surprisingly, the average decrement on HRQoL compared to the condition specific 
baseline was generally smaller for respondents with a single health condition compared to 
respondents with the same health condition plus any comorbidities.  For several conditions 
the decrement was more than halved.  The majority of analytic models use cohorts defined to 
match those in the clinical studies used to represent the effectiveness of treatment.  Therefore 
the data from cohorts with comorbidities are potentially more relevant as few clinical data are 
derived from patients who do not have any of the prevalent conditions, particularly in older 
aged cohorts.  However, some clinical studies do impose strict exclusion criteria relating to 
comorbidities.  Consequently the clinical and HRQoL evidence and the cohort definitions 
used in economic models should be considered carefully when selecting the baseline HSUV 
used to estimate the benefits of treatments. 
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Our exploratory analyses suggest the decrement on HRQoL associated with health conditions 
are not constant across age.  Some conditions showed an increasing trend and others showed a 
decreasing trend.  This may be due to the prevalence of comorbidities and additional research 
in this area would be beneficial.  In particular research in health conditions which have a 
substantial effect on HRQoL and cohorts subgrouped by severity of condition would be 
interesting. 
 
The mean EQ-5D score for individuals reporting no health condition is comparable to the 
average (EQ-5D = 0.952) obtained from individuals with no condition in the US Medical 
Expenditure Panel Survey (n=40,846).[10]  While we found a strong trend for HSUVs to 
decrease by age irrespective of health status, we observed a levelling or increase in mean 
HRQoL in the age groups 65 to 70 years.  This has also been reported in data collected using 
several different preference-based measures in the US.[11]  Comparing our results generated 
using the UK EQ-5D algorithm, with the US EQ-5D values for non institutionalised US 
respondents (n=3,816) in the US based National Health Measurement Study, there is a much 
larger variation in age related mean EQ-5D scores in our dataset.  The US mean scores ranged 
from approximately 0.89 for both males and females aged between 35 and 44 years to 
approximately 0.85 (0.82) for males (females) aged between 75 and 89 years.  Using the data 
from all respondents irrespective of health status, the mean EQ-5D scores are 0.915 and 0.650 
for the subgroups aged 30 to 35 years and 80 to 85 years respectively in our data.  However, 
our results are comparable with those reported in a larger study using data (n=22,523) from 
the US Medical Expenditure Panel Survey (2001): mean UK EQ-5D scores 0.897 (0.864) for 
males (females) aged 30-39 years and 0.711 (0.622) for males (females) aged 80-89 
years.[12] 
 
There are limitations with the data used in this study.  In particular the health conditions are 
self-reported and no information was collected that could be used to determine either the 
duration of the health condition or the severity of the condition.  There was a great deal of 
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individual variation for respondents reporting the same health condition and this could be 
partly attributable to the wide range in severity of and duration of condition included within a 
single subgroup.  The coded conditions are not exhaustive and it is probable that some 
respondents had health conditions which are not included in the analyses.  As the conditions 
that are not identified are not prevalent this is unlikely to affect our main findings.  The 
surveys did not sample from people in nursing homes or other institutions who are likely to 
have lower HRQoL on average than those residing in their own home.  This is more likely to 
have an effect on the HSUVs for the older aged cohorts and it could be that the actual average 
EQ-5D scores for these subgroups are lower than we report.  This may have an impact on the 
age related trends in the decrements for the different health conditions and additional research 
in this area would be interesting. 
 
Some of the mean HSUVs for subgroups with a particular condition are lower than the 
corresponding values for subgroups without the condition or those from respondents 
irrespective of health status which initially appears counter intuitive.  For the analyses 
conducted on subgroups with just one health condition, one possible explanation for higher 
HSUVs for the respondents with a condition is that the average person in the general 
population will in fact have a lower HSUV as the combined decrements on HRQoL for the 
prevalent conditions could be larger than the decrement for the single condition. 
 
Decision analytic models of health care interventions require a baseline HRQoL profile to 
accurately calculate the benefits of treatment.  These data would ideally be derived from 
respondents who do not have the exact definition of the health condition(s) being modelled.  
When these data are not available, the current study provides a number of age and health 
condition stratified HSUVs that can be used to assess the benefits of treatment compared to 
the average person who does not have the condition.  Our results suggest age adjusted HSUV 
from the general population could be used as the baseline when modelling the benefits of 
treatment for individuals with comorbidities.  However, these data are not appropriate when 
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modelling interventions in patients with a single health condition.  Our findings require 
validation in additional datasets and additional research examining subgroups of patients with 
precisely defined health conditions would be beneficial. 
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Table 1: Primary analyses, comparing mean EQ-5D scores for respondents subgrouped by health condition (plus any other health condition), respondents of a 
similar age without the health condition, and respondents of a similar age irrespective of health status 
     Respondents affected by  
the health condition 
(and any other health condition)   
Respondents of a similar  
age not affected by the  
health condition  
Respondents of a similar  
age irrespective of health status 
(i.e. general population) 
 Mean 
Age 
n Mean  
EQ-5D 
95% CI  
of the mean 
n Mean  
EQ-5D 
95% CI  
of the mean 
n Mean  
EQ-5D 
95% CI  
of the mean 
Cancer (neoplasm) including lumps, 
mass masses, tumours and growths and 
benign (nonmalignant) lumps and cysts 
60.9 820 0.697 (0.657, 0.736) 560 0.798 (0.755, 0.839)* 574 0.795 (0.754, 0.836)‡ 
Diabetes including  hyperglycemia 60.4 1772 0.714 (0.695, 0.731) 592 0.845 (0.823, 0.866)† 628 0.841 (0.819, 0.862)‡ 
Other endocrine/metabolic diseases 56.4 1566 0.771 (0.747, 0.793) 655 0.830 (0.797, 0.861)† 696 0.821 (0.790, 0.852) 
Mental illness/anxiety/depression/nerves 45.5 1332 0.606 (0.585, 0.626) 645 0.878 (0.861, 0.894)† 682 0.856 (0.836, 0.876)‡ 
Mental handicap 31.7 31* 0.654 (0.524, 0.783) 691 0.916 (0.901, 0.929) 692 0.916 (0.901, 0.929) 
Epilepsy/fits/convulsions 43.2 267 0.715 (0.671, 0.758) 703 0.896 (0.880, 0.910)† 709 0.894 (0.878, 0.909)‡ 
Migraine/headaches 44.0 393 0.777 (0.745, 0.808) 704 0.888 (0.871, 0.904)† 714 0.885 (0.868, 0.902)‡ 
20 
Other problems of nervous system 52.3 926 0.584 (0.552, 0.615) 607 0.846 (0.825, 0.865)† 631 0.834 (0.813, 0.854)‡ 
Cataract/poor eye sight/blindness 62.8 543 0.700 (0.669, 0.731) 530 0.814 (0.786, 0.841)† 538 0.812 (0.785, 0.839)‡ 
Other eye complaints 61.2 470 0.741 (0.683, 0.797) 567 0.794 (0.752, 0.835) 574 0.795 (0.754, 0.836) 
Poor hearing/deafness 61.2 586 0.768 (0.742, 0.794) 567 0.795 (0.753, 0.835)† 574 0.795 (0.754, 0.836) 
Tinnitus/noises in the ear 61.0 125 0.749 (0.684, 0.812) 572 0.795 (0.753, 0.835) 574 0.795 (0.754, 0.836) 
Meniere's disease/ear complaints causing 
balance problems 
60.9 154 0.704 (0.649, 0.759) 572 0.795 (0.754, 0.836) 574 0.795 (0.754, 0.836) 
Other ear complaints 42.8 81 0.879 (0.826, 0.932) 708 0.894 (0.878, 0.909) 709 0.894 (0.878, 0.909) 
Stroke/cerebral haemorrhage/cerebral 
thrombosis 
67.8 360 0.541 (0.488, 0.593) 589 0.828 (0.804, 0.851)† 603 0.822 (0.798, 0.846)‡ 
Heart attack/angina 68.5 929 0.628 (0.602, 0.653) 569 0.826 (0.802, 0.850)† 603 0.822 (0.798, 0.846)‡ 
Hypertension/high blood pressure 62.3 3172 0.777 (0.765, 0.788) 451 0.812 (0.787, 0.835) 522 0.811 (0.788, 0.832) 
Other heart problems 64.0 1349 0.672 (0.649, 0.694) 496 0.802 (0.771, 0.831)† 528 0.795 (0.765, 0.824)‡ 
Piles/haemorrhoids including varicose 
veins in anus 
47.9 24* 0.778 (0.644, 0.911) 645 0.857 (0.832, 0.882) 647 0.858 (0.832, 0.882) 
Varicose veins/phlebitis in lower 59.0 102 0.794 (0.730, 0.857) 665 0.804 (0.780, 0.828) 668 0.804 (0.780, 0.827) 
21 
extremities 
Other blood vessels/embolic 59.8 476 0.644 (0.611, 0.676) 619 0.846 (0.824, 0.866)† 628 0.841 (0.819, 0.862)‡ 
Bronchitis/emphysema 65.2 336 0.584 (0.541, 0.625) 565 0.835 (0.809, 0.860)† 577 0.828 (0.801, 0.853)‡ 
Asthma 44.2 2452 0.797 (0.779, 0.814) 674 0.890 (0.873, 0.907)† 714 0.885 (0.868, 0.902)‡ 
Hayfever 36.9 416 0.920 (0.904, 0.935) 790 0.910 (0.893, 0.925) 803 0.910 (0.894, 0.925) 
Other respiratory complaints 56.1 686 0.697 (0.671, 0.723) 676 0.824 (0.791, 0.855)† 696 0.821 (0.790, 0.852)‡ 
Stomach ulcer/abdominal hernia/rupture 59.3 619 0.688 (0.654, 0.720) 650 0.806 (0.781, 0.830)† 668 0.804 (0.780, 0.827)‡ 
Other digestive complaints (stomach, 
liver, pancreas, bile ducts, small intestine 
duodenum, jejunum and ileum) 
51.6 666 0.734 (0.707, 0.760) 620 0.836 (0.815, 0.856)† 631 0.834 (0.813, 0.854)‡ 
Complaints of bowel/colon (large 
intestine, caecum, bowel, colon, rectum) 
52.5 925 0.698 (0.665, 0.731) 609 0.832 (0.808, 0.855)† 625 0.829 (0.805, 0.852)‡ 
Complaints of teeth/mouth/tongue 46.8 30* 0.550 (0.346, 0.753) 651 0.895 (0.878, 0.910) 652 0.894 (0.878, 0.910) 
Kidney complaints 52.7 297 0.657 (0.609, 0.703) 621 0.833 (0.809, 0.855)† 625 0.829 (0.805, 0.852)‡ 
Urinary tract infection 59.5 36* 0.705 (0.546, 0.862) 668 0.804 (0.780, 0.827) 668 0.804 (0.780, 0.827) 
Other bladder problems/incontinence 61.1 146 0.619 (0.557, 0.679) 571 0.796 (0.755, 0.837)† 574 0.795 (0.754, 0.836)‡ 
22 
Reproductive system disorders 50.1 545 0.782 (0.757, 0.806) 662 0.865 (0.846, 0.884)† 668 0.866 (0.847, 0.885)‡ 
Arthritis/rheumatism/fibrositis 62.9 4145 0.597 (0.584, 0.609) 436 0.862 (0.836, 0.888)† 538 0.812 (0.785, 0.839)‡ 
Back problems/slipped disc/spine/neck 50.0 2484 0.649 (0.632, 0.666) 615 0.888 (0.870, 0.905)† 668 0.866 (0.847, 0.885)‡ 
Other problems of bones/joints/muscles 54.9 2526 0.642 (0.628, 0.656) 627 0.854 (0.833, 0.874)† 696 0.821 (0.790, 0.852)‡ 
Infectious and parasitic disease 44.5 79 0.676 (0.605, 0.746) 735 0.879 (0.863, 0.895)† 736 0.879 (0.863, 0.895)‡ 
Disorders of blood and blood forming or 
organs and immunity disorders 
53.7 334 0.728 (0.692, 0.764) 646 0.833 (0.812, 0.853)† 647 0.833 (0.812, 0.854)‡ 
Skin complaints 45.9 684 0.773 (0.733, 0.812) 675 0.855 (0.834, 0.875)† 682 0.856 (0.836, 0.876)‡ 
* Four subgroups with less than the sample size (64 respondents) for assessing significance were not compared for difference in mean EQ-5D scores 
All CIs for mean EQ-5D overlap (p>0.05) when comparing: respondents not affected by the condition versus irrespective of health status 
† CIs for mean EQ-5D do not overlap (p<0.05) when comparing: respondents with the condition versus respondents not affected by the condition 
‡ CIs for mean EQ-5D do not overlap (p<0.05) when comparing: respondents with the condition versus respondents irrespective of health status 
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Table 2: Secondary analyses, comparing mean EQ-5D score for respondents with a single health condition, respondents of a similar age with no health 
condition, and respondents of a similar age irrespective of health condition 
     Respondents affected by  
the one health condition 
(and no other health condition)   
Respondents of a similar  
age with no health condition  
Respondents of a similar  
age irrespective of health status 
(i.e. general population) 
 Mean 
Age 
n Mean  
EQ-5D 
95% CI  
of the mean 
n Mean  
EQ-5D 
95% CI  
of the mean 
n Mean  
EQ-5D 
95% CI  
of the mean 
Cancer (neoplasm) including lumps, 
mass masses, tumours and growths and 
benign (nonmalignant) lumps and cysts 
55.0 282 0.836 (0.801, 0.871) 315 0.952 (0.937, 0.965)† 670 0.835 (0.813, 0.856) 
Diabetes including  hyperglycemia 55.2 537 0.898 (0.883, 0.912) 315 0.952 (0.937, 0.965)† 670 0.835 (0.813, 0.856)‡ 
Other endocrine/metabolic diseases 48.3 422 0.924 (0.909, 0.937) 369 0.948 (0.934, 0.960) 647 0.858 (0.832, 0.882)‡ 
Mental illness/anxiety/depression/nerves 40.6 541 0.709 (0.685, 0.733) 535 0.955 (0.946, 0.964)† 826 0.877 (0.856, 0.897)‡ 
Mental handicap 26.0 11* 0.776 (0.594, 0.957) 399 0.965 (0.954, 0.976) 527 0.940 (0.927, 0.952) 
Epilepsy/fits/convulsions 38.5 102 0.873 (0.837, 0.908) 500 0.953 (0.943, 0.962)† 794 0.903 (0.889, 0.916) 
Migraine/headaches 40.3 132 0.912 (0.880, 0.943) 573 0.955 (0.945, 0.965)† 850 0.907 (0.893, 0.921) 
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Other problems of nervous system 48.2 336 0.695 (0.663, 0.726) 369 0.948 (0.934, 0.960)† 647 0.858 (0.832, 0.882)‡ 
Cataract/poor eye sight/blindness 53.3 97 0.926 (0.897, 0.954) 302 0.936 (0.923, 0.949) 625 0.829 (0.805, 0.852)‡ 
Other eye complaints 49.1 95 0.894 (0.857, 0.930) 349 0.946 (0.933, 0.959)† 645 0.843 (0.802, 0.884) 
Poor hearing/deafness 51.7 146 0.937 (0.914, 0.959) 315 0.931 (0.916, 0.944) 631 0.834 (0.813, 0.854)‡ 
Tinnitus/noises in the ear 59.2 21* 0.903 (0.816, 0.990) 273 0.923 (0.905, 0.940) 668 0.804 (0.780, 0.827) 
Meniere's disease/ear complaints causing 
balance problems 
54.3 40* 0.893 (0.826, 0.960) 319 0.930 (0.913, 0.946) 647 0.833 (0.812, 0.854) 
Other ear complaints 36.1 33* 0.926 (0.869, 0.982) 532 0.956 (0.947, 0.965) 780 0.909 (0.895, 0.923) 
Stroke/cerebral haemorrhage/cerebral 
thrombosis 
65.8 102 0.684 (0.587, 0.780) 216 0.938 (0.917, 0.958)† 644 0.790 (0.763, 0.817) 
Heart attack/angina 67.0 200 0.804 (0.768, 0.840) 193 0.935 (0.914, 0.955)† 617 0.815 (0.791, 0.839) 
Hypertension/high blood pressure 59.8 974 0.916 (0.903, 0.928) 286 0.936 (0.918, 0.953) 628 0.841 (0.819, 0.862)‡ 
Other heart problems 58.2 366 0.822 (0.781, 0.862) 288 0.938 (0.921, 0.953)† 637 0.829 (0.808, 0.849) 
Piles/haemorrhoids including varicose 
veins in anus 
48.2 8* 0.931 (0.822, 1.038) 369 0.948 (0.934, 0.960) 647 0.858 (0.832, 0.882) 
Varicose veins/phlebitis in lower 49.0 36* 0.847 (0.790, 0.903) 349 0.946 (0.933, 0.959) 645 0.843 (0.802, 0.884) 
25 
extremities 
Other blood vessels/embolic 51.8 104 0.807 (0.760, 0.852) 315 0.931 (0.916, 0.944)† 631 0.834 (0.813, 0.854) 
Bronchitis/emphysema 65.0 83 0.789 (0.744, 0.834) 200 0.956 (0.939, 0.973)† 577 0.828 (0.801, 0.853) 
Asthma 37.6 1127 0.931 (0.922, 0.939) 500 0.953 (0.943, 0.962)† 794 0.903 (0.889, 0.916)‡ 
Hayfever 35.8 186 0.961 (0.947, 0.975) 532 0.956 (0.947, 0.965) 780 0.909 (0.895, 0.923)‡ 
Other respiratory complaints 47.9 156 0.818 (0.778, 0.858) 369 0.948 (0.934, 0.960)† 647 0.858 (0.832, 0.882) 
Stomach ulcer/abdominal hernia/rupture 52.5 124 0.891 (0.863, 0.918) 302 0.936 (0.923, 0.949)† 625 0.829 (0.805, 0.852)‡ 
Other digestive complaints (stomach, 
liver, pancreas, bile ducts, small intestine 
duodenum, jejunum and ileum) 
43.9 184 0.875 (0.845, 0.903) 424 0.959 (0.949, 0.967)† 714 0.885 (0.868, 0.902) 
Complaints of bowel/colon (large 
intestine, caecum, bowel, colon, rectum) 
44.2 282 0.878 (0.854, 0.901) 424 0.959 (0.949, 0.967)† 714 0.885 (0.868, 0.902) 
Complaints of teeth/mouth/tongue 34.4 11* 0.667 (0.410, 0.924) 531 0.957 (0.947, 0.966) 763 0.912 (0.898, 0.926) 
Kidney complaints 44.8 81 0.845 (0.799, 0.889) 461 0.952 (0.942, 0.960)† 736 0.879 (0.863, 0.895) 
Urinary tract infection 43.8 7* 0.934 (0.822, 1.046) 424 0.959 (0.949, 0.967) 714 0.885 (0.868, 0.902) 
Other bladder problems/incontinence 50.5 23* 0.891 (0.829, 0.952) 371 0.947 (0.932, 0.961) 668 0.866 (0.847, 0.885) 
26 
Reproductive system disorders 41.6 174 0.882 (0.855, 0.909) 494 0.943 (0.930, 0.956)† 761 0.877 (0.846, 0.908) 
Arthritis/rheumatism/fibrositis 60.1 1358 0.685 (0.662, 0.706) 286 0.936 (0.918, 0.953)† 628 0.841 (0.819, 0.862)‡ 
Back problems/slipped disc/spine/neck 45.5 1106 0.745 (0.727, 0.761) 461 0.952 (0.942, 0.960)† 736 0.879 (0.863, 0.895)‡ 
Other problems of bones/joints/muscles 48.9 942 0.731 (0.709, 0.753) 349 0.946 (0.933, 0.959)† 645 0.843 (0.802, 0.884)‡ 
Infectious and parasitic disease 40.8 33* 0.762 (0.698, 0.824) 535 0.955 (0.946, 0.964) 826 0.877 (0.856, 0.897) 
Disorders of blood and blood forming or 
organs and immunity disorders 
39.7 90 0.876 (0.835, 0.915) 573 0.955 (0.945, 0.965)† 850 0.907 (0.893, 0.921) 
Skin complaints 38.4 210 0.916 (0.892, 0.939) 500 0.953 (0.943, 0.962)† 794 0.903 (0.889, 0.916) 
* Ten subgroups with less than the sample size (64 respondents) for assessing significance were not compared for difference in mean EQ-5D scores 
All CIs for mean EQ-5D do not overlap (p<0.05) when comparing: respondents with no health condition versus respondents irrespective of health status 
† CIs for mean EQ-5D do not overlap (p<0.05) when comparing: respondents with the condition versus respondents with no health condition 
‡ CIs for mean EQ-5D do not overlap (p<0.05) when comparing: respondents with the condition versus respondents irrespective of health status 
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Figure 1: Mean EQ-5D scores stratified by age and number of health conditions 
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Figure 2: Mean EQ-5D scores and average decrements on HRQoL for respondents with “back 
problems/slipped disc/spine/neck” 
Figure 2a: Respondents with “back problems/slipped disc/spine/neck” and any other health 
condition compared to respondents without “back problems/slipped disc/spine/neck” 
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Figure 2b: Respondents with just “back problems/slipped disc/spine/neck” and no other health 
condition compared to respondents with no condition 
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(the number of cases are shown next to data points for respondents who have the condition) 
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APPENDIX 
Table A1: Frequencies of the health conditions 
 Respondents affected by the health condition  
(and any other health condition) 
Respondents affected by just the one health 
condition  
  n mean age Se of the mean n ~ mean age Se of the mean 
No health condition 22449 39.9 (39.6, 40.1)     
Cancer (neoplasm) including lumps, mass 
masses, tumours and growths and benign 
(nonmalignant) lumps and cysts 
820 60.9 (59.3, 62.3) 282 34% 55.0 (52.5, 57.4) 
Diabetes including  hyperglycemia 1772 60.4 (59.6, 61.1) 537 30% 55.2 (53.7, 56.6) 
Other endocrine/metabolic diseases 1566 56.4 (55.4, 57.2) 422 27% 48.3 (46.7, 49.8) 
Mental illness/anxiety/depression/nerves 1332 45.5 (44.6, 46.4) 541 41% 40.6 (39.2, 41.9) 
Mental handicap 31 31.7 (26.9, 36.4) 11 35% 26.0 (19.5, 32.4) 
Epilepsy/fits/convulsions 267 43.2 (41.1, 45.2) 102 38% 38.5 (35.8, 41.1) 
Migraine/headaches 393 44.0 (42.2, 45.8) 132 34% 40.3 (36.9, 43.6) 
Other problems of nervous system 926 52.3 (51.0, 53.4) 336 36% 48.2 (46.0, 50.3) 
30 
Cataract/poor eye sight/blindness 543 62.8 (60.5, 65.0) 97 18% 53.3 (48.0, 58.6) 
Other eye complaints 470 61.2 (58.7, 63.5) 95 20% 49.1 (44.5, 53.5) 
Poor hearing/deafness 586 61.2 (59.3, 63.0) 146 25% 51.7 (48.2, 55.1) 
Tinnitus/noises in the ear 125 61.0 (58.3, 63.7) 21 17% 59.2 (50.3, 68.1) 
Meniere's disease/ear complaints causing 
balance problems 
154 60.9 (58.1, 63.5) 40 26% 54.3 (49.9, 58.6) 
Other ear complaints 81 42.8 (35.7, 49.8) 33 41% 36.1 (25.4, 46.7) 
Stroke/cerebral haemorrhage/cerebral 
thrombosis 
360 67.8 (66.3, 69.2) 102 28% 65.8 (63.1, 68.5) 
Heart attack/angina 929 68.5 (67.5, 69.4) 200 22% 67.0 (65.0, 68.8) 
Hypertension/high blood pressure 3172 62.3 (61.8, 62.8) 974 31% 59.8 (58.8, 60.7) 
Other heart problems 1349 64.0 (62.9, 65.0) 366 27% 58.2 (56.0, 60.4) 
Piles/haemorrhoids including varicose 
veins in anus 
24 47.9 (42.2, 53.5) 8 33% 48.2 (39.7, 56.5) 
Varicose veins/phlebitis in lower 
extremities 
102 59.0 (55.5, 62.4) 36 35% 49.0 (43.0, 54.9) 
31 
Other blood vessels/embolic 476 59.8 (58.1, 61.4) 104 22% 51.8 (48.2, 55.3) 
Bronchitis/emphysema 336 65.2 (63.5, 66.8) 83 25% 65.0 (61.3, 68.6) 
Asthma 2452 44.2 (43.4, 45.0) 1127 46% 37.6 (36.5, 38.6) 
Hayfever 416 36.9 (35.3, 38.4) 186 45% 35.8 (33.7, 37.7) 
Other respiratory complaints 686 56.1 (54.4, 57.7) 156 23% 47.9 (44.1, 51.6) 
Stomach ulcer/abdominal hernia/rupture 619 59.3 (57.7, 60.7) 124 20% 52.5 (49.7, 55.2) 
Other digestive complaints (stomach, liver, 
pancreas, bile ducts, small intestine 
duodenum, jejunum and ileum) 
666 51.6 (50.1, 53.0) 184 28% 43.9 (41.1, 46.6) 
Complaints of bowel/colon (large 
intestine, caecum, bowel, colon, rectum) 
925 52.5 (51.2, 53.8) 282 30% 44.2 (41.8, 46.5) 
Complaints of teeth/mouth/tongue 30 46.8 (39.9, 53.7) 11 37% 34.4 (22.3, 46.3) 
Kidney complaints 297 52.7 (50.3, 54.9) 81 27% 44.8 (40.0, 49.5) 
Urinary tract infection 36 59.5 (53.9, 64.9) 7 19% 43.8 (30.0, 57.5) 
Other bladder problems/incontinence 146 61.1 (57.7, 64.3) 23 16% 50.5 (41.1, 59.8) 
Reproductive system disorders 545 50.1 (48.2, 51.8) 174 32% 41.6 (38.7, 44.4) 
32 
Arthritis/rheumatism/fibrositis 4145 62.9 (62.3, 63.5) 1358 33% 60.1 (58.8, 61.2) 
Back problems/slipped disc/spine/neck 2484 50.0 (49.2, 50.7) 1106 45% 45.5 (44.4, 46.5) 
Other problems of bones/joints/muscles 2526 54.9 (54.0, 55.8) 942 37% 48.9 (47.5, 50.2) 
Infectious and parasitic disease 79 44.5 (40.4, 48.5) 33 42% 40.8 (35.2, 46.3) 
Disorders of blood and blood forming or 
organs and immunity disorders 
334 53.7 (49.9, 57.4) 90 27% 39.7 (36.1, 43.2) 
Skin complaints 684 45.9 (44.0, 47.8) 210 31% 38.4 (36.3, 40.4) 
~ proportion of respondents affected by the health condition who reported at least one other condition 
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Table A2: Additional age/health condition stratified mean EQ-5D scores for prevalent health conditions 
Age Band 
(years) 
n mean  95% CI  
of mean 
n mean 95% CI  
of mean 
n mean  95% CI  
of mean 
n mean 95% CI  
of mean 
 History of health condition* No history of health condition History of health condition No history of health condition 
 General population irrespective of 
health status (n = 41147) 
No Health condition (n=22449) Arthritis/rheumatism/fibrositis (n=4145) 
<30 8083 0.9383 (0.935,0.941) 6269 0.9633 (0.960,0.965) 45 0.6865 (0.587,0.785) 8038 0.9396 (0.936,0.942) 
30 to ≤ 35 3608 0.9145 (0.907,0.921) 2555 0.9564 (0.951,0.961) 62 0.6526 (0.470,0.834) 3546 0.9196 (0.913,0.925) 
35 to ≤ 40 4020 0.9069 (0.900,0.913) 2675 0.9544 (0.950,0.958) 88 0.6712 (0.575,0.766) 3932 0.9121 (0.906,0.918) 
40 to ≤ 45 3746 0.8824 (0.872,0.891) 2376 0.9513 (0.946,0.956) 154 0.6485 (0.595,0.701) 3592 0.8919 (0.882,0.901) 
45 to ≤ 50 3294 0.8639 (0.852,0.875) 1892 0.9430 (0.936,0.949) 214 0.5859 (0.535,0.635) 3080 0.8824 (0.871,0.893) 
50 to ≤ 55 3156 0.8344 (0.824,0.843) 1555 0.9345 (0.927,0.941) 384 0.5975 (0.558,0.636) 2772 0.8679 (0.859,0.876) 
55 to ≤ 60 3285 0.8222 (0.811,0.833) 1400 0.9296 (0.914,0.944) 482 0.5996 (0.567,0.631) 2803 0.8585 (0.847,0.869) 
60 to ≤ 65 2739 0.8072 (0.793,0.821) 1017 0.9373 (0.928,0.946) 514 0.5902 (0.552,0.627) 2225 0.8546 (0.841,0.867) 
65 to ≤ 70 2993 0.8041 (0.790,0.817) 992 0.9331 (0.921,0.944) 621 0.6024 (0.565,0.639) 2372 0.8560 (0.844,0.866) 
70 to ≤ 75 2501 0.7790 (0.766,0.791) 741 0.9219 (0.909,0.934) 580 0.6045 (0.575,0.633) 1921 0.8293 (0.816,0.841) 
34 
75 to ≤ 80 1895 0.7533 (0.739,0.767) 522 0.8965 (0.881,0.911) 472 0.5864 (0.555,0.617) 1423 0.8066 (0.792,0.820) 
80 to ≤ 85 1199 0.6985 (0.677,0.719) 301 0.8844 (0.866,0.902) 319 0.5509 (0.513,0.588) 880 0.7518 (0.727,0.775) 
>85 655 0.6497 (0.624,0.675) 154 0.8191 (0.784,0.853) 210 0.5198 (0.462,0.577) 445 0.7090 (0.682,0.735) 
 Hypertension/high blood pressure/blood (n = 3172) Other problems of bones/joints/muscles (n=2526) 
<30 20 0.8062 (0.709,0.902) 8063 0.9386 (0.935,0.941) 202 0.7626 (0.726,0.799) 7881 0.9428 (0.939,0.945) 
30 to ≤ 35 26 0.8154 (0.710,0.919) 3582 0.9153 (0.907,0.922) 136 0.7438 (0.700,0.786) 3472 0.9218 (0.914,0.929) 
35 to ≤ 40 79 0.8641 (0.810,0.917) 3941 0.9077 (0.901,0.913) 142 0.685 (0.634,0.735) 3878 0.9146 (0.908,0.920) 
40 to ≤ 45 108 0.7745 (0.701,0.847) 3638 0.8854 (0.875,0.894) 185 0.6794 (0.631,0.726) 3561 0.8925 (0.883,0.902) 
45 to ≤ 50 200 0.8032 (0.759,0.847) 3094 0.8676 (0.855,0.879) 185 0.6407 (0.586,0.695) 3109 0.8774 (0.865,0.888) 
50 to ≤ 55 306 0.7666 (0.727,0.805) 2850 0.8414 (0.831,0.851) 210 0.6021 (0.558,0.645) 2946 0.8502 (0.840,0.859) 
55 to ≤ 60 416 0.778 (0.747,0.808) 2869 0.8284 (0.816,0.840) 229 0.6426 (0.601,0.683) 3056 0.8354 (0.824,0.846) 
60 to ≤ 65 426 0.8089 (0.777,0.840) 2313 0.8069 (0.791,0.822) 226 0.5847 (0.536,0.632) 2513 0.8255 (0.811,0.839) 
65 to ≤ 70 573 0.7849 (0.761,0.808) 2420 0.8084 (0.792,0.823) 267 0.5962 (0.530,0.662) 2726 0.8253 (0.813,0.836) 
70 to ≤ 75 453 0.7749 (0.746,0.803) 2048 0.7799 (0.765,0.794) 265 0.605 (0.561,0.648) 2236 0.7988 (0.786,0.811) 
75 to ≤ 80 296 0.7417 (0.709,0.773) 1599 0.7554 (0.739,0.770) 212 0.6125 (0.569,0.655) 1683 0.7719 (0.757,0.786) 
80 to ≤ 85 194 0.6867 (0.633,0.740) 1005 0.7009 (0.678,0.723) 169 0.548 (0.495,0.600) 1030 0.7254 (0.704,0.746) 
35 
>85 75 0.6853 (0.617,0.753) 580 0.6456 (0.618,0.672) 98 0.5498 (0.484,0.615) 557 0.6704 (0.642,0.698) 
 Back problems/slipped disc/spine/neck (n=2484) Asthma (n=2452) 
<30 218 0.7623 (0.728,0.795) 7865 0.9432 (0.940,0.946) 531 0.9024 (0.886,0.918) 7552 0.9408 (0.937,0.944) 
30 to ≤ 35 152 0.7035 (0.657,0.749) 3456 0.9241 (0.916,0.931) 211 0.8658 (0.832,0.898) 3397 0.9174 (0.909,0.924) 
35 to ≤ 40 246 0.7193 (0.675,0.763) 3774 0.9184 (0.912,0.924) 240 0.8531 (0.817,0.889) 3780 0.9102 (0.903,0.916) 
40 to ≤ 45 258 0.6573 (0.583,0.731) 3488 0.8993 (0.891,0.906) 199 0.7676 (0.670,0.864) 3547 0.8893 (0.881,0.897) 
45 to ≤ 50 269 0.6728 (0.632,0.713) 3025 0.8813 (0.869,0.892) 196 0.7073 (0.591,0.823) 3098 0.874 (0.865,0.882) 
50 to ≤ 55 267 0.6152 (0.565,0.665) 2889 0.8538 (0.844,0.862) 185 0.7591 (0.701,0.817) 2971 0.8392 (0.829,0.848) 
55 to ≤ 60 297 0.6139 (0.571,0.655) 2988 0.8433 (0.832,0.854) 200 0.7604 (0.707,0.812) 3085 0.8262 (0.814,0.837) 
60 to ≤ 65 248 0.5586 (0.488,0.628) 2491 0.8329 (0.821,0.844) 164 0.6229 (0.558,0.686) 2575 0.818 (0.804,0.831) 
65 to ≤ 70 180 0.6378 (0.592,0.683) 2813 0.8155 (0.801,0.829) 174 0.7122 (0.661,0.763) 2819 0.8092 (0.795,0.823) 
70 to ≤ 75 155 0.565 (0.501,0.628) 2346 0.7941 (0.781,0.806) 152 0.6909 (0.629,0.751) 2349 0.7851 (0.772,0.797) 
75 to ≤ 80 99 0.5456 (0.470,0.620) 1796 0.7645 (0.750,0.778) 120 0.7168 (0.659,0.773) 1775 0.7559 (0.741,0.770) 
80 to ≤ 85 66 0.549 (0.465,0.632) 1133 0.7074 (0.686,0.728) 56 0.6936 (0.594,0.792) 1143 0.6987 (0.677,0.719) 
>85 29 0.5142 (0.374,0.654) 626 0.6553 (0.629,0.681) 24 0.7018 (0.624,0.778) 631 0.6474 (0.621,0.673) 
 Diabetes. incl. hyperglycemia (n=1772) Other endocrine/metabolic (n=1566)  
36 
<30 43 0.8595 (0.773,0.945) 8040 0.9386 (0.935,0.941) 59 0.8551 (0.809,0.900) 8024 0.9389 (0.935,0.942) 
30 to ≤ 35 41 0.7271 (0.579,0.874) 3567 0.9165 (0.909,0.923) 45 0.8214 (0.736,0.906) 3563 0.9156 (0.908,0.923) 
35 to ≤ 40 59 0.8312 (0.765,0.896) 3961 0.9079 (0.901,0.914) 80 0.8718 (0.814,0.928) 3940 0.9076 (0.901,0.913) 
40 to ≤ 45 85 0.7321 (0.651,0.812) 3661 0.8858 (0.876,0.895) 109 0.7923 (0.734,0.850) 3637 0.8851 (0.875,0.894) 
45 to ≤ 50 118 0.7611 (0.697,0.824) 3176 0.8675 (0.855,0.879) 119 0.7085 (0.543,0.873) 3175 0.8706 (0.861,0.879) 
50 to ≤ 55 142 0.703 (0.644,0.761) 3014 0.8409 (0.831,0.850) 140 0.7876 (0.729,0.845) 3016 0.8368 (0.827,0.846) 
55 to ≤ 60 173 0.7199 (0.669,0.770) 3112 0.8277 (0.816,0.838) 198 0.7589 (0.713,0.804) 3087 0.826 (0.814,0.837) 
60 to ≤ 65 245 0.656 (0.593,0.718) 2494 0.8216 (0.808,0.834) 198 0.7905 (0.747,0.833) 2541 0.8085 (0.793,0.823) 
65 to ≤ 70 303 0.7254 (0.685,0.765) 2690 0.8124 (0.798,0.826) 233 0.7942 (0.758,0.830) 2760 0.8048 (0.790,0.818) 
70 to ≤ 75 279 0.7114 (0.673,0.749) 2222 0.7878 (0.774,0.801) 175 0.7487 (0.699,0.798) 2326 0.7813 (0.768,0.794) 
75 to ≤ 80 167 0.6555 (0.604,0.706) 1728 0.763 (0.748,0.777) 109 0.7125 (0.651,0.773) 1786 0.7555 (0.741,0.769) 
80 to ≤ 85 83 0.6977 (0.638,0.756) 1116 0.6985 (0.676,0.720) 75 0.599 (0.524,0.673) 1124 0.7043 (0.682,0.725) 
>85 34 0.6214 (0.507,0.734) 621 0.651 (0.624,0.677) 26 0.5316 (0.388,0.674) 629 0.6543 (0.628,0.680) 
 Other heart problems (n=1349) Mental illness/anxiety/depression/nerves (n=1332) 
<30 43 0.8201 (0.747,0.892) 8040 0.9389 (0.935,0.942) 188 0.6835 (0.639,0.727) 7895 0.944 (0.940,0.947) 
30 to ≤ 35 16 0.8645 (0.781,0.947) 3592 0.9148 (0.907,0.922) 132 0.627 (0.559,0.694) 3476 0.9243 (0.917,0.931) 
37 
35 to ≤ 40 28 0.8147 (0.741,0.888) 3992 0.9075 (0.901,0.913) 159 0.6232 (0.573,0.672) 3861 0.9176 (0.911,0.923) 
40 to ≤ 45 43 0.628 (0.431,0.824) 3703 0.8855 (0.876,0.894) 171 0.6167 (0.564,0.669) 3575 0.8955 (0.886,0.904) 
45 to ≤ 50 51 0.7086 (0.641,0.775) 3243 0.8664 (0.854,0.877) 136 0.5356 (0.463,0.607) 3158 0.8782 (0.867,0.889) 
50 to ≤ 55 67 0.6759 (0.589,0.762) 3089 0.8376 (0.828,0.847) 142 0.563 (0.503,0.622) 3014 0.8458 (0.836,0.855) 
55 to ≤ 60 112 0.686 (0.626,0.745) 3173 0.8269 (0.815,0.837) 147 0.5901 (0.511,0.668) 3138 0.8342 (0.823,0.844) 
60 to ≤ 65 159 0.6234 (0.531,0.714) 2580 0.8189 (0.805,0.832) 78 0.5522 (0.476,0.627) 2661 0.8143 (0.800,0.828) 
65 to ≤ 70 209 0.6866 (0.626,0.747) 2784 0.8132 (0.799,0.827) 57 0.6398 (0.534,0.745) 2936 0.8068 (0.793,0.820) 
70 to ≤ 75 225 0.6719 (0.625,0.718) 2276 0.7892 (0.776,0.802) 48 0.5862 (0.471,0.700) 2453 0.783 (0.770,0.795) 
75 to ≤ 80 186 0.6885 (0.643,0.733) 1709 0.7602 (0.745,0.774) 29 0.5762 (0.423,0.728) 1866 0.7561 (0.742,0.770) 
80 to ≤ 85 127 0.6137 (0.555,0.672) 1072 0.707 (0.684,0.729) 28 0.5333 (0.384,0.682) 1171 0.7021 (0.681,0.723) 
>85 83 0.5171 (0.441,0.592) 572 0.6692 (0.642,0.695) 17 0.5524 (0.361,0.743) 638 0.6523 (0.626,0.677) 
 Heart attack/angina (n=929) Other problems of nervous system (n=926) 
<30 1 0.088 na 8082 0.9384 (0.935,0.941) 67 0.735 (0.669,0.800) 8016 0.94 (0.936,0.943) 
30 to ≤ 35 2 0.4244 (-3.59,4.442) 3606 0.9148 (0.907,0.922) 36 0.7242 (0.609,0.838) 3572 0.9163 (0.908,0.923) 
35 to ≤ 40 6 0.7015 (0.352,1.050) 4014 0.9072 (0.900,0.913) 77 0.6408 (0.564,0.717) 3943 0.9119 (0.905,0.918) 
40 to ≤ 45 10 0.5502 (0.250,0.850) 3736 0.8834 (0.873,0.892) 92 0.5847 (0.512,0.656) 3654 0.8893 (0.879,0.898) 
38 
45 to ≤ 50 23 0.5502 (0.250,0.850) 3271 0.8664 (0.855,0.877) 86 0.5043 (0.320,0.688) 3208 0.8748 (0.865,0.883) 
50 to ≤ 55 51 0.6643 (0.514,0.814) 3105 0.8374 (0.827,0.846) 107 0.4949 (0.417,0.571) 3049 0.845 (0.835,0.854) 
55 to ≤ 60 103 0.5863 (0.520,0.652) 3182 0.8291 (0.818,0.840) 117 0.6003 (0.537,0.663) 3168 0.8295 (0.818,0.840) 
60 to ≤ 65 112 0.6167 (0.544,0.688) 2627 0.8147 (0.800,0.828) 73 0.5558 (0.471,0.639) 2666 0.814 (0.800,0.827) 
65 to ≤ 70 143 0.6687 (0.611,0.726) 2850 0.811 (0.797,0.824) 86 0.6128 (0.538,0.687) 2907 0.8091 (0.795,0.822) 
70 to ≤ 75 157 0.6501 (0.594,0.705) 2344 0.7875 (0.774,0.800) 71 0.5527 (0.463,0.641) 2430 0.7851 (0.772,0.797) 
75 to ≤ 80 167 0.6523 (0.598,0.706) 1728 0.7628 (0.748,0.777) 51 0.5092 (0.395,0.623) 1844 0.76 (0.746,0.773) 
80 to ≤ 85 95 0.621 (0.557,0.684) 1104 0.7058 (0.683,0.727) 41 0.5189 (0.410,0.627) 1158 0.7051 (0.683,0.726) 
>85 59 0.6122 (0.523,0.700) 596 0.653 (0.626,0.679) 22 0.5806 (0.416,0.744) 633 0.6519 (0.626,0.677) 
 Complaints of bowel/colon (n=925) Cancer (n=820) 
<30 79 0.876 (0.840,0.911) 8004 0.9389 (0.935,0.942) 27 0.7952 (0.669,0.921) 8056 0.9387 (0.935,0.941) 
30 to ≤ 35 58 0.7895 (0.709,0.869) 3550 0.9163 (0.908,0.923) 21 0.8435 (0.713,0.973) 3587 0.9149 (0.907,0.922) 
35 to ≤ 40 71 0.7871 (0.704,0.869) 3949 0.9091 (0.902,0.915) 32 0.8461 (0.744,0.948) 3988 0.9074 (0.901,0.913) 
40 to ≤ 45 65 0.5958 (0.357,0.834) 3681 0.8878 (0.879,0.895) 33 0.7186 (0.617,0.819) 3713 0.8842 (0.874,0.893) 
45 to ≤ 50 64 0.6706 (0.575,0.765) 3230 0.8678 (0.856,0.879) 43 0.5728 (0.171,0.974) 3251 0.868 (0.858,0.877) 
50 to ≤ 55 85 0.7138 (0.627,0.800) 3071 0.8379 (0.828,0.847) 49 0.7283 (0.591,0.865) 3107 0.8361 (0.826,0.845) 
39 
55 to ≤ 60 106 0.6808 (0.593,0.768) 3179 0.8273 (0.816,0.838) 89 0.6724 (0.600,0.744) 3196 0.8262 (0.815,0.837) 
60 to ≤ 65 85 0.5847 (0.493,0.675) 2654 0.8138 (0.799,0.827) 84 0.6737 (0.607,0.739) 2655 0.8113 (0.797,0.825) 
65 to ≤ 70 100 0.7257 (0.658,0.793) 2893 0.8063 (0.792,0.819) 133 0.7297 (0.652,0.807) 2860 0.8078 (0.794,0.821) 
70 to ≤ 75 89 0.6455 (0.575,0.716) 2412 0.7841 (0.771,0.796) 109 0.6819 (0.609,0.754) 2392 0.7831 (0.770,0.795) 
75 to ≤ 80 65 0.6319 (0.529,0.734) 1830 0.7577 (0.743,0.771) 122 0.6599 (0.595,0.724) 1773 0.76 (0.745,0.774) 
80 to ≤ 85 38 0.5881 (0.457,0.719) 1161 0.7019 (0.680,0.723) 47 0.6627 (0.567,0.758) 1152 0.6998 (0.678,0.721) 
>85 20 0.4607 (0.294,0.626) 635 0.6546 (0.628,0.680) 31 0.5643 (0.439,0.689) 624 0.654 (0.628,0.679) 
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Figure 3: Mean EQ-5D scores and decrements on HRQoL for cohorts with 
“hypertension/high blood pressure/blood” 
Figure 3a: Respondents with “hypertension/high blood pressure/blood” and any other health 
condition compared to respondents without “hypertension/high blood pressure/blood ” 
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Figure 3b: Respondents with just “hypertension/high blood pressure/blood”and no other 
health condition compared to respondents with no condition 
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(the number of cases are shown next to data points for respondents who have the condition) 
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Figure 4: Mean EQ-5D scores and decrements on HRQoL for cohorts with 
“arthritis/rheumatism/fibrositis” 
Figure 4a: Respondents with “arthritis/rheumatism/fibrositis” and any other health condition 
compared to respondents without “arthritis/rheumatism/fibrositis” 
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Figure 4b: Respondents with just “arthritis/rheumatism/fibrositis” and no other health 
condition compared to respondents with no condition 
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(the number of cases are shown next to data points for respondents who have the condition) 
